The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.

INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.

The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.

PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.

Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.

BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.

Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.

Evopoint reveals intriguing but opaque first-in-human data for XNW27011.